SLC5A2 and chronic kidney disease: Except for the renin–angiotensin system (RAS) blockers, including angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) [4,5,6], and sodium-glucose cotransporter-2 (SGLT-2) inhibitors [7,8], few agents have been proven to protect against the development or progression of CKD.